VICTORIA, BC, Jan. 27, 2015 /CNW/ - T-Bird Pharma Inc.
(TSXV:TPI) ("T-Bird" or the "Company"), a
pharmaceutical company focused on developing premium quality
medical marijuana products and a licensed producer ("LP") under the
Marihuana for Medical Purposes Regulations (Canada) ("MMPR"), wishes to announce that
Sandra (Sandy) Pratt has joined the
Company as Chief Financial Officer, replacing Chris Taylor who has stepped down to return to
his private practice. Taylor will remain involved with the
Company at the Board level by continuing on as Corporate Secretary
and operationally as an RPIC and consultant. "Chris'
background in our history and operations is valuable so we are very
pleased to see that he has agreed to remain involved with the
Company at the Board level" noted David
Raffa, Chairman of the Board. Added Raffa, "the
addition of Sandy to our team represents another step in increasing
the operational experience within our company as we commercialize
our operation. We are very pleased she has agreed to join our
team."
Ms. Pratt is a CPA/CA who began her career in public practice
with Deloittes where she had a large number of public and private
company clients. Ms. Pratt left private practice to join
Angiotech in its early stages and experienced the challenges and
excitement of being a core member of a high growth pharma company.
During her tenure with Angiotech, first as controller and
then as Director of Finance, the company grew from an organization
of two to 45 companies, and from pre-revenue to over $300 million in revenues. Ms. Pratt was a
key part of the finance and M&A teams.
More recently, Ms. Pratt served as Vice-President of Finance at
the Oak Bay Marine Group where her duties covered all aspects of
financial operations. In addition to her finance role, she
also led sales and marketing and was co-responsible for all aspects
of the conglomerate's operations together with one other senior
officer. "It is Sandy's broad operational experience that
attracted us to her," noted Dr. Bin Huang, CEO of the
Company. "Sandy's skill set goes beyond that of a typical CFO
having been involved at various points in her career with
operations, business development, sales and marketing and human
resources."
Ms. Pratt has been granted an option to acquire up to 350,000
common shares vesting over three years.
About T-Bird and Thunderbird
T-Bird Pharma Inc. is the parent company of Thunderbird
Biomedical Inc., a wholly owned private subsidiary formed in
January, 2013. The principal activities of Thunderbird are
the production of marijuana from its Victoria, British Columbia production
facility, as regulated by the Marihuana for Medical Purposes
Regulations (Canada). Thunderbird obtained a
medical marijuana license to undertake the production of medical
marijuana in February 2014, being the
fifth company in Canada to obtain
such a license. Thunderbird was acquired by T-Bird in
September, 2013.
ON BEHALF OF THE BOARD
"David Raffa"
Chairman
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Cautionary Statements Regarding Forward Looking
Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable
securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking statements" involve
known and unknown risks and uncertainties that could cause actual
and future events to differ materially from those anticipated in
such statements.
Forward-looking statements include, but are not limited to,
statements with respect to commercial operations, including
production and sales of medical marijuana, anticipated revenues,
projected size of market, quantities of future medical marijuana
production, completion of production facilities and other
information that is based on forecasts of future results, estimates
of amounts not yet determinable and assumptions of
management.
T-Bird Pharma Inc. (the "Company") does not intend, and
does not assume any obligation, to update these forward-looking
statements except as required by law. These forward-looking
statements involve risks and uncertainties relating to, among other
things, results of production and sale activities, the Company's
historical experience with medical marijuana operations, uninsured
risks, regulatory changes, availability of production facilities,
timeliness of government approvals and the granting of permits and
licenses, changes in prices, actual operating and financial
performance of facilities, equipment and processes relative to
specifications and expectations. Actual results may differ
materially from those expressed or implied by such forward-looking
statements.
SOURCE T-Bird Pharma Inc.